Recent studies suggest that FGF21 treatment can mitigate various age-related metabolic disorders, including atherosclerosis, obesity, T2DM, and cardiovascular diseases [14,15]. The gene discussed is FGF21; the disease is obesity due to melanocortin 4 receptor deficiency.